Prevents ischemic complications of unstable angina and non-Q-wave myocardial infarction. Sold as Fragmin. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Dalteparin Sodium (sold as Fragmin), first approved Dec 22, 1994, with 7 new uses approved and 0 published complete response letters.
| Optimizing Anticoagulation in Pregnancies With Mechanical Heart ValvesPregnancy, Prosthetic Heart Valve · Mount Sinai Hospital, Canada | Not applicable | Recruiting | Jun 22, 2026 |
| The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.Bariatric Surgery, Anti-Xa Activity · University College Dublin | Not applicable | Not yet recruiting | Apr 30, 2026 |
| Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From ClexaneHealthy Participants Study, The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants · Egyptian International Pharmaceutical Industries Co | Phase 1 | Not yet recruiting | Apr 8, 2026 |
| Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in InfertilityInfertility · Tang-Du Hospital | — | Recruiting | Mar 27, 2026 |
| Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic MalignanciesLymphoma, Leukemia · Medical University of Gdansk | Not applicable | Recruiting | Dec 8, 2025 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events PreventionHip Fracture Surgery, Cardiovascular Prevention · McMaster University | Phase 3 | Not yet recruiting | Nov 14, 2025 |
| Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum ThrombosisVenous Thromboembolism (VTE), Postpartum · Marc Blondon | Phase 3 | Recruiting | Aug 24, 2025 |
| Edoxaban Steady-State PK/PD in Adults With Nephrotic SyndromeNephrotic Syndrome, Hypoalbuminemia · Peking University People's Hospital | Not applicable | Not yet recruiting | Aug 11, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA